Supplementary material to article by G. Yosipovitch et al. “Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis”

Fig. S1. Sensitivity analysis of relative contribution of itch and Psoriasis Area and Severity Index (PASI) scores on Dermatology Life Quality Index (DLQI) symptom and feelings domain score change at Week 4 and Week 12. ETN: etanercept; IXE Q2W: ixekizumab 80 mg once every 2 weeks; IXE Q4W: ixekizumab 80 mg once every 4 weeks; PBO: placebo.